Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

 
• By Joseph Haas
Kidney
BMS and Exelixis hope they'll have the best combo data for first-line RCC

More from Clinical Trials

More from R&D